JP2018511607A - Antimicrobial composition - Google Patents

Abstract

The present invention relates to amino acids, amino acid derivatives, amino acid salts, amino acid derivative salts, or mixtures thereof; two or more antimicrobial quaternary ammonium compounds or at least one antimicrobial quaternary ammonium compound and The present invention relates to an antimicrobial component comprising chlorhexidine or a salt thereof; and an antimicrobial composition comprising a polar solvent, and a preparation comprising the antimicrobial composition. In particular, the present invention relates to antimicrobial compositions that can be used on the skin.

Description

  The present invention relates to an antimicrobial composition and a formulation comprising the antimicrobial composition. In particular, the present invention relates to antimicrobial compositions that can be used on the skin.

  Microorganisms such as bacteria and viruses such as Norovirus, Poliovirus and Adenovirus are known to cause health hazards due to infection or contamination. Along with fungi, yeast and other microorganisms, these microorganisms can cause spoilage of items such as food, clothing and can cause unpleasant odors. If microorganisms are present on the surface of a substrate such as skin, they can replicate rapidly and form colonies.

  Many antimicrobial agents can destroy microorganisms that exist in a wide range of environments. For example, antimicrobial agents are known that can be used in medical, industrial, commercial, household, and marine environments. Many of the known antimicrobial agents have been previously included in compositions used in these environments for a variety of applications.

  Known antimicrobial agents and compositions containing these antimicrobial agents work through a number of different mechanisms.

  For example, many antimicrobial agents are toxic to microorganisms and thus destroy the microorganisms they come into contact with. Examples of this type of antimicrobial agent include hypochlorite (bleach), phenol, and its compounds, and copper, tin, and arsenic salts.

  However, many of these antimicrobial agents are effective against microorganisms and are appropriate for certain environments, but their mechanism is due to their harmful effects on human health or skin condition. They can make them unsuitable or disadvantageous for topical application to human skin. For example, hypochlorite bleach is very effective at killing microorganisms on solid surfaces, but is unsuitable for skin application due to its corrosive properties. Also, these materials tend to be effective in a humid environment for sterilization and cleaning, but fail immediately after drying.

  Many skin antiseptics are alcoholic. These are typically alcohol-containing preparations designed to be applied to the hand to reduce the number of viable microorganisms on the hand. Such preparations typically contain 60% to 95% ethanol or isopropanol. However, although isopropyl alcohol has established antibacterial properties, it has the disadvantage that it can cause dryness and skin irritation when used regularly. As a result, some people may hate to use creams, soaps and other compositions containing, for example, significant concentrations of isopropanol.

  Some antimicrobial agents are very toxic to humans and animals and are dangerous to handle. Therefore, professional handling, processing and equipment are required for safe handling. Thus, the production and disposal of compositions containing this type of antimicrobial agent can be problematic. There may also be problems associated with the use of compositions containing this type of antimicrobial agent, particularly in consumer materials where it is difficult to ensure that they are used for a specified purpose.

  As used herein, unless otherwise indicated by context, “toxicity” is intended to refer to toxicity to complex organisms such as mammals. Words indicating "toxicity" should be interpreted accordingly.

  The increasing scrutiny of environmental credibility of chemicals further restricts the use of antimicrobial agents for general use, as well as topical application to the skin. For example, if some antimicrobial agents enter the environment, they can harm other organisms. They are also very stable and can persist in the environment for extended periods causing build-up and residual concentration concerns.

  Because of these factors, the list of effective and available antimicrobial agents, especially for use on the skin, is becoming more limited and the burden of registering new antimicrobial agents is higher. At the same time, following outbreaks like MRSA in hospitals, there is a growing interest in sanitizing both humans and property.

  There is a need to provide compositions for various uses and uses, such as compositions for use on the skin, such as hand wiping agents, that have antimicrobial properties and that address one or more of the problems described above. is there. However, this is not easy to achieve. Regulations such as Biocidal Products Regulations (Directive 98/8 / EC) that regulate the use of antimicrobial agents in terms of both the nature and amount of a given antimicrobial agent that can be used is there. Furthermore, the potential reactivity when an antimicrobial agent is present in the composition is important because some antimicrobial agents become inactive upon chemical reaction. Even when an antimicrobial agent is not inactivated by a chemical reaction, its activity may be inhibited by other components of the composition.

  Surprisingly, the inventors have found that the aforementioned drawbacks can be overcome by certain combinations of ingredients. It has also been found that compositions containing these combinations of ingredients can have some surprising and unexpected properties.

  A list or discussion of a document clearly disclosed herein is not necessarily to be taken as an admission that the document is part of the state of the art or is general knowledge.

The present invention
(I) amino acids, amino acid derivatives, amino acid salts, or amino acid derivative salts or mixtures thereof;
(Ii) an antimicrobial component comprising two or more antimicrobial quaternary ammonium compounds or at least one antimicrobial quaternary ammonium compound and chlorhexidine or a chlorhexidine salt; and
(Iii) an antimicrobial composition comprising a polar solvent.

Amino acids are well-known organic compounds essential to life. They are characterized by having an amine (NH ₂ ) functional group attached to the carbon adjacent to the carboxylic acid (CO ₂ H) functional group with side chains specific for amino acids. Amino acids have the general formula

  Since amino acids have both amine and carboxylic acid groups, they can act as both bases and acids. At low pH, the main form has neutral carboxylic acid groups and positive ammonium ions (net charge + 1). At high pH it has negative carboxylate groups and neutral amino groups (net charge -1). At intermediate pH, amino acids usually have both a negative carboxylate group and a positive ammonium group and therefore have a net zero charge.

Arginine is one of the most common amino acids and is shown below.

  Further examples of common amino acids are glycine, lysine, glutamate, glutamine, aspartate, asparagine, histidine, proline, methionine, cysteine, serine, threonine, isoleucine, phenylalanine, tyrosine, tryptophan, valine and leucine. The structure of these amino acids is well documented.

  The term “amino acid” also includes chains of amino acids such as peptides and polypeptides. A peptide is formed when individual amino acids are linked together via a peptide (amide) bond formed by the reaction of an amine group of one amino acid with a carboxyl group of another amino acid. The shortest peptides are dipeptides consisting of two amino acids joined by a single peptide bond, followed by tripeptides, tetrapeptides, and the like. A polypeptide is a long, continuous, unbranched peptide chain.

The term “amino acid derivative” refers to an amino acid in which the α-amino and / or carboxyl functional group is substituted with an alternative organic group, or an amino acid in which a side chain functional group of the amino acid is substituted with an alternative organic group, Alternatively, it means an amino acid in which the α-amino and / or carboxyl functional group is substituted with an alternative organic group and / or an amino acid in which the functional group of its side chain is also substituted with an alternative organic group. Alternative organic groups include, but are not limited to, alkenyl, phenyl, amide, ester, alcohol, and ether groups or combinations thereof. An example of an amino acid derivative is N-lauroyl-L-arginine ethyl ester, whose structure is shown below.

The term “amino acid salt” refers to a cationic or anionic form of an amino acid in combination with a counter ion that is an ion of opposite charge. The cationic form of an amino acid is formed by the transfer of positively charged hydrogen ions from an acid to an amino group in the amino acid. The counter ion is derived from an acid from which hydrogen ions are transferred. The anionic form of an amino acid is formed by the loss of positively charged hydrogen ions from the carboxylic acid group of the amino acid. In this case, the counter ion is derived from a base to which hydrogen ions move. An example of an amino acid salt is arginine lactate commercially available from AH Care L65. AH Care L65 is composed of a mixture of lactic acid and arginine. The structure of arginine lactate is shown below.

The term “salt of a derivative of an amino acid” means a cationic or anionic form of an amino acid derivative as defined above in combination with a counter ion that is an ion of opposite charge. The cationic form of the amino acid is formed by the transfer of positively charged hydrogen ions from the acid to the amino group in the amino acid derivative. The counter ion is derived from an acid from which hydrogen ions are transferred. The anionic form of the amino acid derivative is formed by the loss of positively charged hydrogen ions from the carboxylic acid group of the amino acid derivative. In this case, the counter ion is derived from a base to which a hydrogen ion moves. An example of a salt of an amino acid derivative is N-lauroyl-L-arginine ethyl ester monohydrochloride commercially available as Aminat G, whose structure is shown below.

  The salts of amino acids or amino acid derivatives used in the present invention include hydrochloride, tartrate, malonate, succinate, succinate, malate, glutamate, pyroglutamate and aspartate. However, it is not limited to these. In one aspect, the salt of an amino acid or amino acid derivative is a phosphonate or phosphorus-containing salt, such as a monoalkyl phosphate ion, monoalkenyl phosphate ion, monoalkyl phosphonate ion, or monoalkenyl phosphonate ion, or 8 to 20 carbon atoms. It is not like having a linear or branched alkyl or alkenyl group.

  Component (i) may comprise hydrophilic amino acids or salts or derivatives of such amino acids, or salts of such derivatives. The hydrophilic amino acid may have a hydrophilic side chain, or may have a hydrophilic side chain and be positively or negatively charged.

  Component (i) may comprise, for example, a positively charged amino acid or a salt or derivative of such an amino acid, or a salt of such a derivative.

  Amino acid derivatives may be hydrophilic as a result of modifications to the amino acid. For example, amino acids can be modified to be positively or negatively charged.

  The hydrophilic amino acids defined above are typically water soluble.

  Water soluble means that an amino acid or a salt or derivative of such an amino acid, or a salt of such a derivative, typically has a solubility of at least about 0.5 g per kg of water in water at 25 ° C. To do. For example, at least about 1 g / kg water, for example at least about 10 g / kg water, or at least about 50 g / kg water.

  Amino acid salts and derivatives suitable for use in the present invention and salts of such derivatives are typically water soluble.

  Amino acids suitable for use in the present invention can also be classified by their hydrophobicity index. This index is described, for example, by Kyte, J. et al. and Doolittle, R .; , 1982, “A simple method for displaying the hydrostatic character of a protein”, J mol. Biol. 157: 105-132. As those skilled in the art will appreciate, the higher the value of the hydrophobicity index, the more hydrophobic the amino acid. Amino acids suitable for use in the present invention include amino acids having a hydrophobicity index value of 0 or less (eg, −2 or less). Such amino acid salts and derivatives and salts of such derivatives are suitable for use in the present invention. Arginine and its salts and derivatives and salts of such derivatives are suitable for use in the present invention. Arginine has a hydrophobicity index value of -4.5.

  Alternatively or additionally, amino acids suitable for use in the present invention can be classified by isoelectric point (pI), ie, a pH at which the net charge on the amino acid is zero. At pH lower than the isoelectric point, the amino acid is positively charged. In certain compositions of the invention, the amino acid is preferably positively charged. In this embodiment, amino acids having a pI higher than the pH of the composition are used.

  Amino acids suitable for use in the present invention include 5 or more pi, such as 6 or 6.25 or more, or 8 or 10 or more amino acids. Such amino acid salts and derivatives and salts of such derivatives are suitable for use in the present invention. Arginine and its salts and derivatives and salts of such derivatives are suitable for use in the present invention. Arginine has a pI of 10.76.

  Amino acids that are particularly suitable for use in the present invention include amino acids having a hydrophobicity index of 0 or less, such as −2 or less, and a pi of 6 or more, 6.25 or more, or 8 or more, or 10 or more. . Salts and derivatives of these amino acids and salts of such derivatives are also particularly suitable for use in the present invention.

  The composition of the present invention comprises chlorhexidine or a chlorhexidine salt. Examples of suitable chlorhexidine salts include chlorhexidine acetate, formate, gluconate, hydrochloride, isethionate, lactate and succinate. For example, suitable salts include, but are not limited to, chlorhexidine diphosphanylate, chlorhexidine digluconate, chlorhexidine diacetate, chlorhexidine dihydrochloride, chlorhexidine dichloride, chlorhexidine diiodate, chlorhexidine diperchlorate, chlorhexidine dinitrate Chlorhexidine sulfate, chlorhexidine sulfate, chlorhexidine sulfite, chlorhexidine diacid phosphate, chlorhexidine difluoride phosphate, chlorhexidine diformate, chlorhexidine dipropionate, chlorhexidine diiodobutyrate, chlorhexidine di-n-valerate, dichlorp Chlorhexidine, chlorhexidine succinate, chlorhexidine succinate, chlorhexidine malate, chlorhexidine tartrate , Chlorhexidine dimonoglycolate, Chlorhexidine monodiglycolate, Chlorhexidine dilactate, Chlorhexidine di-α-hydroxyisobutyrate, Chlorhexidine diglycol heptonate, Chlorhexidine di-isothionate, Chlorhexidine dibenzoate, Chlorhexidine dicinnamate, Dimandel Acid chlorhexidine, chlorhexidine diisophthalate, chlorhexidine isoethionate, chlorhexidine di-2-hydroxynaphthoate, and chlorhexidine embonate.

  A specific example of a chlorhexidine salt that can be used in the composition of the present invention is chlorhexidine digluconate.

  The quaternary ammonium antimicrobial agent (s) used in the present invention are typically water soluble at room temperature and room pressure.

式中、Ｒ^１及びＲ^２はそれぞれ独立して、直鎖、非置換及び中断されていないＣ_８−１２アルキル基である。一態様では、基Ｒ^１及びＲ^２は、同じ数の炭素原子を含むが、これは本質的ではなく、Ｒ^１及びＲ^２が、使用され得る異なる数の炭素原子を含む化合物である。Ｘ⁻は、塩化物、臭化物、フッ化物、ヨウ化物のようなハロゲン化物アニオン、またはスルホン酸塩、サッカリン酸塩、炭酸塩もしくは重炭酸塩である。 Suitable antimicrobial quaternary ammonium compounds include compounds of formula (A) shown below.

Wherein R ¹ and R ² are each independently a straight chain, unsubstituted and uninterrupted C _8-12 alkyl group. In one aspect, the groups R ¹ and R ² contain the same number of carbon atoms, but this is not essential, and are compounds in which R ¹ and R ² contain different numbers of carbon atoms that can be used. X ⁻ is a halide anion such as chloride, bromide, fluoride, iodide, or a sulfonate, saccharinate, carbonate or bicarbonate.

In one aspect, X ⁻ is a phosphonate salt or a phosphorus-containing salt, such as a monoalkyl phosphate ion, monoalkenyl phosphate ion, monoalkyl phosphonate ion, or monoalkenyl phosphonate ion, or a straight chain having 8 to 20 carbon atoms. Or it is not like having a branched alkyl or alkenyl group.

式中、ｍは８から１８であり、Ｘ⁻は、塩化物、臭化物、フッ化物、ヨウ化物のようなハロゲン化物アニオン、またはスルホン酸塩、サッカリン酸塩、炭酸塩または重炭酸塩である。式（Ｂ）の化合物は、一般に、ベンズアルコニウム化合物と呼ばれる。塩化ベンズアルコニウムは、Ｃ_８−１８アルキル基、特に直鎖、非置換及び中断されていないアルキル基ｎ−Ｃ_８Ｈ_１７からｎ−Ｃ_１８Ｈ_３７、主にｎ−Ｃ_１２Ｈ_２５（ドデシル）、ｎ−Ｃ_１４Ｈ_２９（テトラデシル）、及びｎ−Ｃ_１６Ｈ_３３（ヘキサデシル）の混合物として提供され及び／または使用される。好ましくは、ｍは８、１０、１２、１４及び／または１６である。最も好ましくは、ｍは８から１２であり、例えば８、１０及び／もしくは１２または１２から１６、例えば１２、１４及び／もしくは１６である。 Suitable antimicrobial quaternary ammonium compounds also include benzalkonium compounds having the formula (B) shown below.

Where m is 8 to 18 and X ⁻ is a halide anion such as chloride, bromide, fluoride, iodide, or a sulfonate, saccharinate, carbonate or bicarbonate. The compound of formula (B) is generally called a benzalkonium compound. Benzalkonium chloride is a C _8-18 alkyl group, especially a linear, unsubstituted and uninterrupted alkyl group n-C ₈ H ₁₇ to n-C ₁₈ H ₃₇ , mainly n-C ₁₂ H ₂₅ (dodecyl). ), N-C ₁₄ H ₂₉ (tetradecyl), and n-C ₁₆ H ₃₃ (hexadecyl). Preferably m is 8, 10, 12, 14, and / or 16. Most preferably, m is from 8 to 12, such as 8, 10, and / or 12 or 12 to 16, such as 12, 14, and / or 16.

In the compound of formula (A), the R ¹ and R ² groups are each independently a linear unsubstituted uninterrupted C _8-12 alkyl group, such as 8, 9, 10, 11 or An alkyl group containing 12 carbon atoms. R ¹ and R ² may be the same, for example, both R ¹ and R ² may be alkyl groups containing 8, 9, 10, 11 or 12 carbon atoms.

The benzalkonium compound also includes derivatives of benzalkonium compounds in which the alkyl group C _m H _{2m + 1} shown below can be substituted with another organic group. Such organic groups include, but are not limited to, alkenyl, phenyl, amide, ester, alcohol, and ether groups or combinations thereof.

An example of such a benzalkonium compound derivative is diisobutylphenoxyethoxyethyl-dimethylbenzylammonium chloride, whose INCI name is benzethonium chloride (typically abbreviated as BENZ). The structure of benzethonium chloride is shown below.

  The anion of each quaternary ammonium compound in the composition of the present invention may be the same or different. For example, the anion of the compound of formula (A) may be the same as or different from the anion of the compound of formula (B). In one aspect, the anion of each compound is a chloride anion.

  In one aspect of the present invention, the composition comprises two or more antimicrobial quaternary ammonium compounds, the compound of formula (A) and the compound of formula (B) may be present, or the composition is One or more compounds of formula (A) or two or more compounds of formula (B) may be included.

  Examples of quaternary ammonium compounds of formula (A) include di-n-decyldimethylammonium chloride, octyldecyldimethylammonium chloride and dioctyldimethylammonium chloride.

  Examples of commercially available compounds of formula (A) include Thor's Actide DDQ 40, Lonza's Bardac 2240, Lonza's Bardac 2280, and Mason Chemical Company, USA's Macquat 4480E.

  Examples of quaternary ammonium compounds of formula (B) include N, N-benzyldimethyloctylammonium chloride, N, N-benzyldimethyldecylammonium chloride, N-dodecyl-N-benzyl-N, N-dimethylammonium chloride. N-tetradecyl-N-benzyl-N, N-dimethylammonium chloride, N-hexadecyl-N, N-dimethyl-N-benzylammonium chloride, N, N-dimethyl-N-benzylN-octadecylammonium chloride, and Of the mixture.

  It will be appreciated that a single CAS number often refers to two or more blends or mixtures. The CAS classification of commercial preparations typically covers blends that contain a particular compound in an amount within a defined range. The compositions having the CAS numbers quoted above are only examples of compositions having a given CAS number that can be used in the present invention.

  In the compositions of the present invention, the antimicrobial quaternary ammonium compound is typically not polymerized.

  Examples of commercially available compounds of formula (B) include Thor's Actide BAC 50M, Lonza's Barquat MB50 / 80, Lonza's Lonzagard Benzethonium Chloride USP.

  Typically, the antimicrobial quaternary ammonium compound used in the composition of the present invention is di-n-decyldimethylammonium chloride (DDAC (CAS No. 7173-51-5)), benzalkonium chloride ( BAC), for example, selected from the group consisting of benzalkonium chloride of the above formula (B) wherein m is 8. This benzalkonium chloride has CAS number 68424-85-1 and benzethonium chloride (BENZ).

  The amount of component (i) and antimicrobial component (ii) present in the composition of the present invention depends on many factors such as the intended use of the composition and the particular compound (s) used. And change.

  For example, as will be appreciated by those skilled in the art, higher concentrations of (i) and / or (ii) may be required to provide sterilization as compared to providing sterilization or disinfection.

  The antimicrobial component (ii) can consist essentially of at least one antimicrobial quaternary ammonium compound and chlorhexidine or a chlorhexidine salt.

  The antimicrobial component (ii) can consist of at least one antimicrobial quaternary ammonium compound and chlorhexidine or a chlorhexidine salt.

  An alternative antimicrobial component (ii) can consist essentially of two or more antimicrobial quaternary ammonium compounds without chlorhexidine.

  The composition of the present invention contains two or more antimicrobial quaternary ammonium compounds or at least one antimicrobial quaternary ammonium compound and chlorhexidine or a chlorhexidine salt as the only antimicrobial compound in the composition. Can do. Alternatively, the compositions of the present invention may contain other suitable antibiotic drug (s) (b) as described in the EPA (US Environmental Protection Agency) list and Appendix I and Appendix 3 of the EC Biological Weapons Directive. Can be included.

  Typically, the compound contained in the antimicrobial component (ii) is a compound suitable for application to the skin. For example, the European Commission's delegation regulation (EU) No. 4 August 2014 Humans such as compounds approved by the European Commission when used in product type 1 products listed in Appendix II of 1062/2014 and / or approved by the FDA (Food and Drug Administration) It is a compound that meets the necessary regulatory approvals for sanitation.

  Suitable antimicrobial agents (b) that may be included in the antimicrobial component (ii) include antimicrobial agents that are not quaternary ammonium compounds. Preferably, these additional antimicrobial agents are water soluble at room temperature and pressure.

  Examples of suitable additional antimicrobial agents include, but are not limited to, polymeric biguanidines (eg, polyhexamethylene biguanidine (PHMB)), lactic acid, silver, silver salts such as silver chloride, silver carbonate, citric acid Silver, silver dihydrogen citrate, octenidine HCl, amphoteric compound, iodophor, phenolic compound, amine antimicrobial agent and nitrogenous heterocyclic compound, orthophenylphenol (OPP), nitrobromopropane (eg bronopol (INN) 2-bromo-2-nitropropane-1,3-diol), naturally occurring biocidal compounds (eg, honey and honey extracts such as those containing methylglyoxal), flavedoid antimicrobial agents, and Examples include essential oils.

  In one aspect, the compositions of the present invention do not include inorganic antimicrobial agents such as those containing silver. In this embodiment, the optional additional antimicrobial agent is an organic antimicrobial agent.

  In one aspect, the composition of the present invention may be free of PHMB or free of polymeric biguanide. For example, they do not contain biguanides in addition to chlorhexidine.

  In one aspect of the invention, the antimicrobial composition does not contain any isothiazalone and / or any nitrobromopropane such as bronopol and / or any hypochlorite.

  In one embodiment of the present invention, the antimicrobial composition does not contain an antimicrobial compound that is sparingly soluble in water, such as a phenolic compound.

  Typically, when formulated as a ready-to-use composition, the amount of component (i) is about 0.0005 to 10% by weight of the composition, such as about 0.005 to about 5% by weight of the composition. For example, from about 0.01 to about 1% by weight of the composition. These compositions contain less than about 0.5% by weight of the composition, such as components such as 0.02 to 0.3% by weight of the composition, such as about 0.2% or 0.1% by weight ( i) may be contained.

  Typically, when formulated as a ready-to-use composition, the total amount of antimicrobial component (ii) and component (b), if present (ie, antimicrobial quaternary ammonium compounds and chlorhexidine or salts thereof) And a total amount of any additional antimicrobial component (b)) from about 0.001 to about 10% by weight of the composition, for example from about 0.005 to about 5% by weight of the composition, for example about It can be from 0.01 to about 1% by weight.

  For compositions of the invention formulated for use as a hand sanitizer, the amount of antimicrobial component (ii) can be from about 0.05 to about 0.5% by weight.

  Antimicrobial component (ii) may comprise equal amounts of quaternary ammonium compounds and chlorhexidine, or a salt thereof. For example, if the total amount of antimicrobial component is about 0.2% by weight of the composition, the amount of quaternary ammonium compound is about 0.1% and the amount of chlorhexidine or its salt is about 0.1%. Will.

  Alternatively, the antimicrobial component may comprise different amounts of quaternary ammonium compounds and chlorhexidine.

  Typically, in the compositions of the present invention, the ratio of component (i) to antimicrobial component (ii) ranges from 10: 1 to 1:10.

  The composition of the present invention comprises a polar solvent (iii). Suitable polar solvents include, but are not limited to water, alcohols, glycol ethers and mixtures thereof.

Suitable alcohols include methanol, ethanol, n-propanol, isopropanol, a mixture of propanol isomers, n-butanol, sec-butanol, tert-butanol, iso-butanol, a mixture of butanol isomers, 2-methyl-1- Examples include, but are not limited to, linear or branched C ₁ to C ₅ alcohols such as butanol, n-pentanol, mixtures of pentanol isomers and amyl alcohol (mixtures of isomers), and mixtures thereof. Not.

  Preferred polar solvents for use in the compositions of the present invention include, but are not limited to, water, ethanol, isopentidiol, monopropylene glycol, hexylene glycol, 3-methoxy-3-methyl-1-butanol (MMB). , N-propanol, isopropanol, ethylene glycol ether, propylene glycol ether, butyl diglycol (BDG) and mixtures thereof. In one aspect, the composition comprises water or a mixture of water and one or more alcohols selected from the above alcohols. In such a mixture, it is preferable that water is a main component. The polar solvent may consist essentially of water or may consist of water.

  When the composition of the present invention comprises an alcohol, the alcohol is typically present in an amount that is less than that required to provide the antimicrobial effect, but the alcohol may be dried. Present at a concentration that is thought to improve. For example, the compositions of the present invention comprise up to about 30% alcohol, such as 20 to 30% alcohol or less than about 20% alcohol, such as about 15 to about 20% alcohol.

  It will be appreciated that the percentage of alcohol may depend on the use of the composition. For example, when used on a wipe, the composition of the present invention may contain up to 20% alcohol.

  In one aspect, the composition of the present invention is substantially free of alcohol. For example, the composition may contain 1% by weight or less of alcohol. For example, the composition may contain less than 1% or 0.5% or 0.1% by weight or less of an alcohol such as isopropanol. As an example, the composition of the present invention may be free of isopropanol or free of alcohol.

  In another aspect, the composition of the present invention may comprise alcohol up to a concentration of 70% by weight, such as up to about 50% by weight.

  The composition may comprise water or a mixture of water and one or more alcohols selected from the above alcohols. In such a mixture, it is preferable that water is a main component.

  For example, the polar solvent can consist of water or consist essentially of water. As another example, the polar solvent may be water and about 0 to about 20% by weight, for example about 15 to about 20% by weight alcohol, such as ethanol or isopropanol.

  The composition of the present invention may be provided in a concentrated form for dilution prior to use or ready for use. The compositions of the present invention are preferably provided in a ready-to-use form, and unless otherwise specified, information regarding the amount provided herein (eg, weight percent or ppm) relates to the ready-to-use composition.

  Typically, the concentrate is provided such that when the concentrate is diluted, the concentrate is 5 to 30 wt%, such as 10 or 20 wt% diluted product.

  Typically, but not essentially, the composition of the present invention will be from about 0.0005% to about 10%, such as from about 0.005% to about 5%, or from 0.01% by weight. A concentration of 1.0% by weight amino acid component (i), and from about 0.001% to about 10% by weight, such as from about 0.005% to about 5.0% by weight, or from 0.01% to 1% Having a concentration of antimicrobial component (ii) by weight. These compositions contain less than about 0.5% by weight of the composition, such as components such as 0.02 to 0.3% by weight of the composition, such as about 0.2% or 0.1% by weight ( i) may be contained.

  The pH of the compositions and formulations used can vary within a wide range, for example from about pH 2 to about pH 12, more preferably from about pH 3 to about pH 10 or from about pH 4.5 to 8. The pH of the formulations used in the present invention may be similar to the pH of known formulations that are intended to be used for the same or similar purposes. For example, formulations intended to come into contact with the skin, such as personal care or emergency formulations, typically have a pH that does not irritate the skin, such as from about pH 3 to about pH 8, such as from about pH 4.5 to about pH 7. It will have a pH that is 5 or about pH 5 to about pH 6.

  When used as a hand sanitizer, the pH of the composition of the present invention is typically about 5 to about 6.

  It will be appreciated that the compositions of the present invention can include other materials commonly used in the art. The nature of the other materials used will depend on the nature of the composition and the intended purpose. One skilled in the art will know which additional materials are suitable for use in different application compositions.

  The compositions of the present invention may contain additional materials such as surfactants, complexing agents, buffers, thickeners, skin conditioning compounds, polar solvents and perfumes.

  The choice of surfactant will depend on the nature of the composition and the intended purpose. Surfactants suitable for use in formulations intended for different purposes are within the knowledge of those skilled in the art. Similarly, the selection of an appropriate amount of surfactant is within the knowledge of one skilled in the art. Suitable surfactants can be selected from nonionic, cationic or amphoteric and mixtures thereof.

  Some compositions of the present invention can include a nonionic surfactant. Suitable nonionic surfactants include, but are not limited to, amine oxides, alkyl polyglucosides, linear and branched 1 and 2 alcohol ethoxylates, and ethoxylated / propoxylated (EOPO) block polymers. Not.

  In one aspect, the composition is substantially free or free of anionic surfactants. In another aspect, the composition of the present invention does not include an amphoteric surfactant.

Some compositions of the present invention can include an amphoteric surfactant. Suitable amphoteric surfactants include C ₆ -C ₂₀ alkyl amphoacetate or amphodiacetate (eg, cocoamphoacetate), C ₁₀ -C ₁₈ alkyl dimethyl betaine, C ₁₀ -C ₁₈ alkyl amidopropyl dimethyl betaine. However, it is not limited to these. Examples include, but are not limited to, the coconut amphoteric surfactant cocoamidopropylbetaine (CAPB) (Surfac B4, CAS 61789-40-9), cocoimidazoline betaine, oleamidopropylbetaine and tall oil imidazoline.

  Some compositions of the present invention can include a cationic surfactant. Suitable cationic surfactants include, but are not limited to, undecylenamidopropyltrimonium methosulphate and cetrimonium chloride.

  Typically, the amount of surfactant present in the composition of the present invention is an amount of about 0.01 to 20% by weight. The amount of surfactant will depend on a number of factors, such as the pH of the composition and the intended use of the composition.

  The composition of the present invention may comprise a complexing agent. The term sequestering agent or chelate is often used interchangeably with the term complexing agent. For purposes of describing the present invention, the term complexing agent includes both sequestering agents and chelates. Complexing agents may be used to help provide a clear composition even when the composition of the present invention is used with hard water. Examples of suitable complexing agents include EDTA (ethylenediaminetetraacetic acid), gluconate, GLDA (glutamic acid diacetic acid) —trade name Dissolvine GL, EDDS (ethylenediamine-N, N′-disuccinic acid), citrate and Including, but not limited to, gluconate or salt of glutaric acid, adipic acid and succinic acid, and mixtures thereof. Where the complexing agent contains a counter ion, the counter ion is preferably a metal. Suitable metal counterions include, but are not limited to Na, Ca, Fe, K, Zn, Mg, and Mn.

  Preferred complexing agents are GLDA (Dissolvine) and EDTA.

  The complexing agent is typically present in an amount of about 100 to 10,000 ppm, preferably about 400 to 3,000 ppm, such as about 500 to 2000 ppm.

  Buffers can be included to adjust the pH of the composition to the required value during storage and use and to maintain it at or near that pH.

  Suitable pH adjusters include acids such as citric acid, sulfamic acid, hydrochloric acid, phosphoric acid, nitric acid, lactic acid, formic acid, acetic acid glycolic acid or gluconic acid, or sodium hydroxide or potassium hydroxide, triethanolamine and carbonates And other inorganic or organic acids or bases, and mixtures thereof.

  To adjust the viscosity of the composition to the value necessary for purposes such as making the composition more stable, facilitating application of the composition, or for aesthetic benefits Can be included. Examples of thickeners include hydroxypropyl methylcellulose stearoxy ether commercially available from Daido chemical corporation under the name Sangelose 90 and polyquaternium 37 supplied from Rheo Lab under the name Kleasol 200ST. It is not limited to these.

  The composition of the present invention may contain a skin conditioning compound. Suitable skin conditioning compounds include, but are not limited to, panthenol, tocopherol acetate, glycerin, polyquaternium compounds, PEG-7-glyceryl cocoate, and silicones, and mixtures thereof. Typically, the compositions of the present invention do not contain mucopolysaccharides.

  The compositions of the present invention may alternatively or additionally contain salts such as alkali metal or alkaline earth metal halides such as NaCl or KCl. In some situations, the use of salt can facilitate the formation of a stable composition.

  The compositions of the present invention may also contain other materials standard in the art such as colorants, fragrances, emollients, antioxidants and mixtures thereof.

  The composition of the present invention may not contain an anionic substance. In the sense of anionic substances, counterions that may be present in any of the materials used in the present invention are not included, for example counterions associated with quaternary ammonium compounds. The compositions of the present invention may be free of anionic polyelectrolytes such as, for example, high molecular weight anionic mucomimetic polymers, polystyrene sulfonic acid polymers and cation exchange resins.

  In use, the compositions of the present invention have been found to have advantageous antimicrobial effects, particularly when applied to the surface of the skin. For example, such a composition has an antimicrobial effect when first applied to a surface (so-called “wetkill”) and can lead to the formation of more permanent biofilms on the surface. It may also have a residual antimicrobial effect in terms of controlling, reducing or preventing formation (so-called “dry kill”).

  The composition of the present invention is also resistant to washing and wiping with water. This means that the composition of the present invention provides a residual antimicrobial effect even when the treated surface is subsequently wiped off and / or washed or rinsed with water.

  The compositions of the invention are particularly suitable for use as a skin or hand disinfectant or on other surfaces. Some compositions are suitable for use on other surfaces. The compositions of the present invention typically provide a residual antimicrobial effect.

  Such compositions can be used in a wide variety of forms and applications for the purpose of skin hygiene. For example, the compositions of the present invention are particularly suitable for formulation into mousses, gels, creams, lotions, liquids, sprays and wipes used for body or skin hygiene such as hand sanitizers.

  When used in a wipe format, the substrate used to prepare the wipe can be made of any suitable woven or non-woven material. Suitable wipe fabric materials include non-woven fiber sheet materials and those made from natural sources such as wood pulp, viscose or other cellulosic materials, silk fibers and keratin fibers. It is not limited to. The material comprises 1 to 100% by weight of cellulosic material. For example, 100% cellulosic materials such as viscose or wood pulp can be used. Other preferred materials include blends of cellulosic and non-cellulosic materials such as blends of viscose and synthetic substrates such as polyester or polypropylene. The blend material may comprise 1 to 99.9% by weight of a cellulosic material such as viscose, for example 20 to 80% or 30 to 70% by weight of a cellulosic material such as viscose.

  The compositions of the present invention can be used in humans and animals for both therapeutic and non-therapeutic purposes. Examples of products for non-therapeutic use include personal care and personal hygiene products. Examples of products for therapeutic purposes include first aid and skin care products.

  The compositions of the present invention may also be in liquid form and may be packaged in a suitable dispenser to provide a foam, mousse or spray when in use. The compositions of the present invention can be used in foot hygiene products, including those used directly on the foot and footwear, particularly for the treatment / deodorization of sports shoes. The compositions of the invention are also used for direct application to the skin or hair, for example hair care products including soaps, bath and shower products, shampoos and anti-dandruff shampoos, hair conditioners, hair styling products such as hair mousses, Gels and sprays, skin care products such as shaving products, cosmetics and hair removal products, deodorants and antiperspirant products, baby cleaning and cleaning products such as baby baths, soaps, wipes, moisturizers, diaper lash creams, infants Can be used in other personal care products such as baby products, including products for cleaning surfaces where regular and frequent baby contact occurs.

  The composition of the present invention is applied directly to the skin surface of an animal or its jacket or fur for use for the purpose of eradicating or inhibiting microorganisms that could otherwise adversely affect the health, well-being or cleanliness of the animal. Can be used as a sanitary cleaning agent in pet products. Such compositions can also be applied to materials such as surfaces that come into contact with animals, and microorganisms can be transferred from animals. The advantage of such an application is that it eradicates or inhibits such microorganisms that can otherwise be transferred to another animal or human and also controls or eliminates by-products produced by such organisms such as malodors. It is. Such pet applications include dirt and odor remover sprays, disinfectant sprays and wipes, outdoor hatch cleaners, cage cleaners, antimicrobial cat litter tray sprays and wipes, dog shampoos and splitters and dogs Cleaning ear wipes, but are not limited to these.

  The composition of the present invention may be used in first aid topical applications to sanitize scratches or wounds on the surface of the skin to prevent or control infections, or athlete feet, warts, warts, spots / acne. It can be used to prevent mild infections such as prevention / treatment products. Accordingly, the present invention provides products for these uses, such as wound care or an emergency product comprising the composition of the present invention.

  The compositions of the present invention may also be used in medical applications such as catheter sterilization, dialysis and other medical devices; inhibition or eradication of viruses such as norovirus, poliovirus or adenovirus; prevention or eradication of persistent biofilms Can do.

  The composition of the present invention can also be used on surfaces other than the skin. Examples of application of the invention to non-skin surfaces include, but are not limited to, surface cleaners such as for use in bathrooms, kitchens, living areas; hard floor cleaners; carpet cleaners; Furniture cleaners; glass / mirror cleaners; toilet care products including solid toilet cleaners such as those designed to be placed in rim equipment and aquariums; liquid toilet cleaners except those containing hypochlorite bleach Dishwashing products such as washing up liquids and preparations from dishwashers such as dishwashing solids (in powder or tablet form) and liquids; laundry products such as solid detergents (in powder or tablet form); liquid detergents '2-in-1' products including fabric conditioners and detergents and fabric conditioners; eg patio cleaners, garden furniture cleaners / treatments, barbecue cleaners Outdoor cleaning products for wood, stone, concrete or plastic such as agents, wall and fence cleaners / treatments; plant sprays such as those intended to remove insects such as aphids from plants; for food preservation Food sprays such as those suitable for use.

  For the avoidance of doubt, where the term "comprising" or "comprises" is used herein, the described composition or formulation or ingredient is the stated material (s) But may optionally include additional materials. When the terms “consisting essentially of” or “consists essentially of” are used, the listed composition (s) or formulation (s) or ingredient (s) listed. As long as any additional materials do not affect the essential properties of the composition, formulation or ingredient, small amounts of other materials (eg up to 5% by weight or 1% by weight) Or up to 0.1% by weight). When the term “consisting of” is used, it means that the described composition or formulation or ingredient must contain only the described material (s). These terms can be applied in a manner similar to process, method and use.

  “Substantially free” means that the composition or formulation or ingredient being described is less than 3% by weight, preferably less than 1% by weight, more preferably less than 0.1% by weight. Means including material. For example, a composition of the present invention that is substantially free of alcohol contains less than 3 wt% alcohol, preferably less than 1 wt% alcohol, more preferably less than 0.1 wt% alcohol.

  The term “antimicrobial agent” means a compound or composition that kills and / or inhibits the growth of microorganisms (microorganisms). The term “microbicidal agent” is used to refer to a compound or composition that kills bacteria. The composition of the present invention is an antimicrobial agent and / or a microbicidal agent.

  The term “disinfectant” or “disinfectant” means to reduce the total number of bacteria on the surface.

  The term “sterilization” means the elimination of microorganisms that achieve sterility (sterile environment).

  Microorganisms or bacteria are microscopic (too small to see with the human eye) organisms. Examples of microorganisms include bacteria, fungi, yeasts, molds, mycobacteria, algal spores, archaea and protists. The microorganism is generally a unicellular or unicellular organism. However, as used herein, the term “microorganism” includes viruses.

  The composition of the present invention may be antibacterial, antifungal, antialgae, antisporal, antiviral, antiyeast and / or antifungal.

  The compositions of the present invention are particularly suitable for use against bacteria such as E. coli.

  As used herein, the terms antibacterial, antifungal, antialgae, antiviral, anti-yeast, and antifungal agents are agents that inhibit the growth of each microorganism, but do not necessarily kill the microorganism, as well as kill each microorganism. Intended to refer to a drug. Thus, for example, the term anti-bacteria includes agents that inhibit bacterial growth but do not necessarily kill bacteria and bacterial agents that kill bacteria.

  Examples of antibacterial agents include myobacterides and Mycobacterium tuberculosis. Preferably, the composition of the invention comprises at least one agent selected from antibacterial, antifungal, antialgae, antisporal, antiviral, antiyeast and antifungal agents and mixtures thereof. More preferably, the composition of the present invention comprises at least one antibacterial, antiviral, antifungal and / or antifungal agent.

  The compositions of the present invention may be effective against a wide range of organisms including gram negative and gram positive bacteria, fungi, yeast, viruses and some sporulating bacteria.

  An advantage of the present invention is that it is possible to prevent a wide range of microorganisms from adhering to and adhering to a surface and thus preventing the formation of a biofilm. The formation of a large number of colonies is also substantially prevented. Thus, the ability of colonies to grow is substantially reduced or even prevented. The present invention is therefore general in the control of microorganisms.

  In one aspect of the invention, the composition can be used to reduce or control biofilm formation.

  As described above, the composition of the present invention advantageously provides a residual antimicrobial effect in which the antimicrobial action continues for a significant period after the initial application of the composition.

  Typically, the compositions of the present invention need not contain substances that are highly toxic to mammals. Antimicrobial agents used in antimicrobial compositions are typically well-known, widely understood and tested antimicrobial agents. The effectiveness of known antimicrobial agents is amplified in the formulations of the present invention. Thus, less toxic antimicrobial agents can be used in antimicrobial compositions. Conversely, known techniques of sanitization use many “new” antimicrobial agents using “more powerful”, more toxic and / or little tested substances. .

  The antimicrobial composition of the present invention does not contain substances that produce highly persistent residues or rinses, or products containing heavy metals and their salts. Therefore, the risk of long-term danger is greatly reduced.

  The antimicrobial composition of the present invention does not interfere with the biochemical reproductive pathway of the microorganism to be controlled. Therefore, the risk of increased resistance and the generation of resistant strains are low.

  The antimicrobial composition of the present invention not only provides an antimicrobial effect during use, but also exhibits a preservative effect on the composition, so it can exhibit a double effect. This typically eliminates the need for additional preservatives to be included in the formulations of the present invention.

  The composition of the present invention usually does not give a feeling of grease to the applied surface.

  According to another aspect of the present invention there is provided the use of a composition of the present invention for controlling, reducing or preventing the formation of microbial colonies on a surface which has been subjected to the composition of the present invention.

  The present invention provides a method for providing a residual antimicrobial effect to a surface, such as a hard surface or skin, comprising the step of applying a composition as defined herein to that surface or skin. The composition can be applied to the surface or skin, for example, by spraying the composition onto the surface or rubbing the composition onto the surface or skin. In one method of the present invention, the method need not include any step other than simply applying the composition to the surface. Accordingly, there is provided a method consisting essentially of, or consisting of, applying the composition to the surface or skin.

  In one aspect of the invention, the surface to which the composition of the invention is applied is a body surface such as skin.

  The antimicrobial composition of the present invention typically decomposes when immersed in water to achieve a rinsing / leachate with low toxicity and short residence time in the environment.

  According to another aspect of the present invention there is provided the use of an antimicrobial composition of the present invention to reduce or prevent the formation of microbial colonies on a surface, eg, skin, which has been subjected to the antimicrobial composition of the present invention. Is done.

  The antimicrobial composition of the present invention is typically made by the method described below.

The method for producing the antimicrobial composition described herein comprises:
(I) a step of stirring and mixing component (iii) and component (ii), and (ii) a step of adding component (i) to components (iii) and (ii).

  In some embodiments, the pH of the solution obtained after step (ii) may require adjustment. Accordingly, the present invention also describes a method for adjusting the pH of the solution after (iii) step (ii).

  Priorities and options for a given aspect, feature or parameter of the present invention are optional and all priorities and options for all other aspects, features and parameters of the present invention, unless the context indicates otherwise. Should be considered disclosed in combination.

  The invention will now be illustrated by the following non-limiting examples.

Example 1-Preparation of Test Samples and Controls The composition described in Table 1 was prepared using the method of Example 1. Commercially available compounds used in the composition are listed below.

  Aminat G is a 20% solution of N-lauroyl-L-arginine ethyl ester monohydrochloride in glycerin supplied by Seppic, the main component of which is a salt of a derivative of the amino acid L-arginine.

  AH Care L65 is an amphoteric hydroxy complex containing amino acids, arginine and lactic acid. This is provided by BASF. Both Aminat G and AH Care L65 are commercial examples containing component (i) of the present invention.

  Actide DDQ 40 supplied by Thor contains 40% di-n-decyldimethylammonium chloride (DDAC). This is an example of component (ii) of the present invention, which is formula type A.

  Actide BAC 50M supplied by Thor contains 50% benzalkonium chloride (BAC), is an example of component (ii) of the present invention, and is of formula type B.

  Chlorhexidine digluconate (CHDG) supplied as a 20% solution by Evonik is a further example of component (ii) of the present invention. Lonzagard Benzacenium Chloride USP supplied by Lonza is a benzalkonium derivative and contains 100% diisobutylphenoxyethoxyethyl-dimethylbenzylammonium chloride (BENZ), also known as benzethonium chloride. This is a further example of component (ii) of the present invention.

  A polar solvent (component (iii)) was placed in an appropriately sized container (typically 1 liter capacity). A small amount of polar solvent was retained to allow final weight adjustment. The required amount of biocide (s) (component (ii)) was then added to the container while the container was stirred for 5 minutes after each biocide addition before the next biocide was added. . The required amount of amino acid, derivative or salt (component (i)) was then added and the vessel was stirred for an additional 5 minutes. The pH was checked and adjusted with lactic acid or sodium hydroxide solution as needed. The solution was then brought to 100% by weight by adding a retained polar solvent and stirred for the last 10 minutes.

  A control sample was prepared according to the same method, except that one or more of components (i), (ii) or (iii) of the present invention was prepared.

In Table 1, the weight percent of composition component (i), Amin G and AH Care L65 of the present invention refers to the amount of commercially available material, and the weight percent of component (ii) of the present invention is the active chemical component, DDAC. -Refers to the amount of di-n-decyldimethylammonium chloride; CHOG-chlorhexidine digluconate; BEHZ-benzethonium chloride; or BAC-benzalkonium chloride.
Table 1

Example 2 Evaluation of Residual Antimicrobial Potency of Test Samples 25 microliters (0.025 ml) of test samples were supplied in duplicate by Vitro-Skin 2 cm × 2 cm sections (supplied by IMS, Inc.) Applied). The test sample was spread on the vitro-skin® surface using a sterile inoculation loop and it was confirmed that approximately 0.5 cm perimeter remained untreated on the edge. The test samples were dried on a vitro-skin® * ₂ at 20 ° C. in an oven with a Petri lid left for 1 hour. The Petri dish was then removed from the oven and a strip of polypropylene wipes saturated with sterile tryptone / saline placed inside. The lid was closed and put back into the oven at 20 ° C. for 4 hours. After this time, the Petri dish was removed from the oven and 10 ul of 1 to 1.5 × 10 ^ 8 cfu / ml was removed. A suspension of E. coli K12 * ₁ prepared in tryptone / saline is added to the surface of the vitro-skin® containing the test sample and spread in a sterile inoculation loop so that the suspension is treated with vitroskin. Stay in the area. The bacterial suspension was left in contact with vitroskin for 5 minutes. After this time, the vitro-skin® was removed from the petri dish and placed in a test tube containing 10 ml neutralization solution. This was shaken gently and allowed to stand for another 5 minutes, after which the tube was vortexed for 1 minute to recover the bacteria from the vitroskin surface. A 1 ml sample of this suspension was then plated on tryptone soy agar and incubated at 37 ° C. for 48 hours. After this time, the log reduction of E. coli K12 was calculated relative to the water treated control.
* ₁ NB. E. coli K12 suspension prepared from “2a” cultures grown on tryptone soy agar for 24 hours at 37 ° C. as described in BS EN microbiological standards, eg EN 1276: 2009)
* ₂ Vitro-skin (R) is a test substrate that mimics the surface properties of human skin. This is a synthetic non-biological product formulated to have topography, pH, critical surface tension and ionic strength similar to human skin. It is a used substrate well known to those skilled in the art for assessing the benefits of topological application of skin care products to the skin, including assessment of the biocidal effect of active ingredients applied to the skin. Examples of published, peer-reviewed vitro-skin studies include US 2009/020202463 A1, which describes a method for evaluating antimicrobial compositions, which is Journal of Antibiotic. Agents and Chemotherapy; 48 (7); 2004 July; 2595-2598; enhanced immediate and residual antiviral and antibacterial efficacy on the surface of the skin; prevention of rhinovirus infection US2012 / 01413396 A1 provides an assessment of the effectiveness of organic acids in hand cleansers for disinfecting compositions that provide long-term antimicrobial properties to a variety of surfaces, including skin evaluated using vitro-skin skin Items are described.

Result formula 1 of Example 2
Formulation 1 and control samples 1, 2, 3, 6, 8, and 9 were made into the compositions described in Table 1 according to the method described in Example 1. The formulation 1 and the control sample were then tested for antimicrobial effects using the method described in Example 2. The results of these tests are shown in Table 2 below.
Table 2

  The results in Table 2 show that the composition of the present invention, ie DDAC in combination with CHDG and Aminat G, has superior antimicrobial performance compared to Control 3, which does not have Aminat G (component (i) of the present invention). It shows that.

  Formulation 1 is also compared to controls 6 and 9, which are DDAC and CHDG used individually in Aminat G, respectively, and controls 1 and 8, which are DDAC and CHDG used individually without Aminat G, respectively. Has excellent antimicrobial performance.

  Control 2 shows that Aminat G has no antimicrobial activity.

Formula 2
Formulation 2 and control samples 1, 2, 4, 6, and 7 were made into the compositions described in Table 1 according to the method described in Example 1. The antimicrobial effect of Formulation 2 and the control sample was then tested according to the method described in Example 2. The results of these tests are shown in Table 3 below.
Table 3

  The results in Table 3 show that the composition of the present invention, ie, DDAC in combination with BAC and Aminat G, has superior antimicrobial performance compared to Control 4, which does not have Aminat G (component (i) of the present invention). It shows that.

  Formulation 2 also has superior antimicrobial performance compared to Controls 6 and 7, which are DDAC and BAC used individually in Aminat G, respectively, and Control 1, which is a DDAC used alone without Aminat G. Have

  Control 2 shows that Aminat G has no antimicrobial activity.

Formula 3
Formulation 3 and control samples 5, 10, 11 and 12 were made into the compositions described in Table 1 according to the method described in Example 1. The antimicrobial effect of Formulation 3 and the control sample was then tested according to the method described in Example 2. The results of these tests are shown in Table 4 below.
Table 4

  The results in Table 4 show that the composition of the present invention, ie DDAC in combination with CHDG and AH Care L65, has superior antimicrobial performance compared to Control 12 which does not have AH Care L65 (component (i) of the present invention). It has shown that.

  Formulation 3 also has superior antimicrobial performance compared to Controls 10 and 11, which are DDAC and CHDG used individually in AH Care L65, respectively.

  Control 5 shows that AH Care L65 has no antimicrobial activity.

Chlorhexidine digluconate (CHDG) supplied as a 20% solution by Evonik is a further example of component (ii) of the present invention. Lonza salt of Benzaseniumu USP you supply is benzalkonium derivative, 100% chloride diisobutyl phenoxyethoxyethyl also known as benzethonium chloride - containing dimethyl benzyl ammonium (BENZ). This is a further example of component (ii) of the present invention.

Claims (41)

(I) an amino acid, a derivative of an amino acid, a salt of an amino acid, a salt of an amino acid derivative, or a mixture thereof;
(Ii) an antimicrobial component comprising two or more antimicrobial quaternary ammonium compounds or at least one antimicrobial quaternary ammonium compound and chlorhexidine or a chlorhexidine salt;
(Iii) an antimicrobial composition comprising a polar solvent.   Component (i) is a hydrophilic amino acid or a salt or derivative of such an amino acid, or a salt of such a derivative, or a hydrophilic derivative of an amino acid, or a salt of a hydrophilic derivative of an amino acid, or a mixture thereof. The composition of claim 1.   The composition according to claim 1 or 2, wherein component (i) is at least one amino acid having a hydrophobicity index of 2 or less, or a salt or derivative of such an amino acid, or a salt of such a derivative.   Component (i) is at least one amino acid having an isoelectric point (pI) of 8 or more or 10 or more, or a salt or derivative of such an amino acid, or a salt of such a derivative. The composition of any one of these.   5. The component according to claim 1, wherein component (i) is a positively charged amino acid, or a salt or derivative of such amino acid, or a salt of such derivative, or a mixture thereof. Composition.   6. The component according to any one of claims 1 to 5, wherein component (i) is selected from arginine, lysine, and histidine, and salts thereof, derivatives thereof and salts of derivatives thereof, or mixtures thereof. Composition.   The composition according to claim 6, wherein component (i) is selected from arginine lactate and N-lauroyl-L-arginine ethyl ester monohydrochloride or mixtures thereof.   The composition according to any one of claims 1 to 7, wherein the chlorhexidine is chlorhexidine digluconate. An antimicrobial quaternary ammonium compound of formula (A),

Wherein R ₁ and R ₂ are each independently a linear, unsubstituted, and uninterrupted C _8-12 alkyl group, X ⁻ is chloride, bromide, fluoride, iodide, etc. A sulfonate, saccharinate, carbonate or bicarbonate) and / or at least one benzalkonium compound of formula (B),

Wherein m is 8 to 18 and X − is a halide anion such as chloride, bromide, fluoride, iodide, or a sulfonate, saccharinate, carbonate or bicarbonate. And / or a composition according to any one of claims 1 to 8, comprising benzethonium chloride. The benzalkonium compounds of formula (B) are benzyldimethyl-n-tetradecyl-ammonium chloride, benzyldimethyl-n-dodecylammonium chloride, benzyl-C ₁₂ -C ₁₆ -alkyl-dimethyl-ammonium chloride, diisobutylphenoxyethoxy chloride. Ethyl-dimethylbenzylammonium (also known as benzethonium chloride) or benzyl-cocoalkyl-dimethyl-ammonium chloride and / or the compound of formula (A) is di-n-decyldimethylammonium chloride, The composition according to claim 6, which is octyldecyldimethylammonium chloride or dioctyldimethylammonium chloride.   The antimicrobial quaternary ammonium compound is selected from the group consisting of di-n-decyldimethylammonium chloride (DDAC), benzalkonium chloride (BAC), and benzethonium chloride (BENZ). Composition.   Said antimicrobial component (ii) comprises (a) chlorhexidine or a chlorhexidine salt, and (b) di-n-decyldimethylammonium chloride and / or benzalkonium chloride of the formula (B) as defined in claim 9. 12. A composition according to any one of claims 1 to 11 comprising.   13. The composition of claim 12, comprising a benzalkonium chloride of formula (B), wherein m is 8, 10 or 12.   14. A composition according to any one of the preceding claims comprising a quaternary ammonium compound with CAS number 7173-51-5 and / or 68424-85-1.   15. A composition according to any one of claims 1 to 14, comprising an additional antimicrobial component (b).   The additional antimicrobial component (b) is polymeric biguanidine, silver, octenidine HCl, amphoteric compound, iodophor, phenolic compound, isothiazarone, nitrobromopropane, nitrogen-based heterocyclic compound, alkylbetaine, alkylamine oxide, anion The composition according to claim 15, which is selected from hydrophilic amino acid surfactants and amine antimicrobial agents, and mixtures thereof.   17. A composition according to any one of claims 1 to 16, wherein the amount of component (i) is about 0.0005 to 10% by weight of the composition.   18. The composition of claim 17, wherein the amount of component (i) is about 0.005 to about 5% by weight of the composition.   19. The composition of claim 18, wherein the amount of component (i) is about 0.01 to about 1% by weight of the composition.   20. A composition according to any one of claims 1 to 19, wherein the total amount of component (ii) and, if present, component (b) is from about 0.001 to about 10% by weight of the composition.   21. The composition of claim 20, wherein the total amount of component (ii) and, if present, component (b) is from about 0.005 to about 5% by weight of the composition.   23. The composition of claim 21, wherein the total amount of component (ii) and, if present, component (b) is from about 0.01 to about 1% by weight of the composition.   23. The composition of any one of claims 1-22, wherein the pH of the composition is from about 4.5 to about 8.   24. A composition according to any one of claims 1 to 23, wherein the composition further comprises a complexing agent.   The complexing agents are EDTA (ethylenediaminetetraacetic acid), gluconate, GLDA (glutamic acid diacetic acid), EDDS (ethylenediamine-N, N′-disuccinic acid), DPTA (diethylenetriaminepentaacetic acid), HEDTA (hydroxyethyl-ethylenediaminetriacetic acid). ), MGDA (methyl glycine diacetic acid), PDTA (1,3-propylenediaminetetraacetic acid), and EDG (ethanol diglycine acid), and mixtures thereof.   The polar solvent is selected from water, ethanol, n-propanol, isopropanol, ethylene glycol ether, propylene glycol ether, butyl diglycol (BDG), and dipropylene glycol methyl ether (trade name Dowanol DPM), and mixtures thereof. 26. The composition of any one of claims 1 to 25.   27. A composition according to claim 25 or 26, wherein the composition is substantially free of alcohol.   28. A composition according to any one of claims 1 to 27, which provides a residual antimicrobial effect during use.   29. Use of a composition according to any one of claims 1 to 28 for substantially reducing or controlling the formation of microbial colonies on or on a surface.   30. Use according to claim 29 for reducing or controlling biofilm formation.   29. A method for substantially reducing or controlling the formation of microbial colonies on or on a surface, comprising applying to the surface a composition according to any one of claims 1 to 28.   32. The method of claim 31, for reducing or controlling biofilm formation.   29. A method for destroying, preventing or reducing microbial adhesion and / or adherence to a surface, comprising applying to the surface a composition according to any one of claims 1 to 28.   32. Use according to claim 29 or method according to claim 30 or 31, wherein the surface is skin.   29. A hand disinfectant comprising an antimicrobial composition as defined in any one of claims 1 to 28.   A wound care product comprising an antimicrobial composition as defined in any one of claims 1 to 28.   29. An antimicrobial biological wipe comprising a substrate and an antimicrobial composition as defined in any one of claims 1 to 28.   29. A composition according to any one of claims 1 to 28 for use in the manufacture of a product for reducing or controlling the formation of microbial colonies on the skin or wound.   29. A composition according to any one of claims 1 to 28, used to reduce or control the formation of microbial colonies on the skin or wound.   A composition, use, or method as generally described herein.   A composition, use, or method as generally described herein with reference to the examples.